The effect of subchronic administration of 7-(4-fluorobenzyloxy)-2,3- dimethyl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526), a novel acid pump antagonist, on gastric acid secretion and gastrin levels in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 326, Issue 1, 2008, Pages 163-170

  Ito, Keiichi ^a   Kinoshita, Kazuya ^a   Tomizawa, Atsuyuki ^a   Morikawa Inomata, Yuka ^a   Inaba, Fumi ^a   Fujita, Yoshifumi ^a   Tabata, Keiichi ^a   Shibakawa, Nobuhiko ^b  

^a DAIICHI SANKYO CO   (Japan)

^b Ube Laboratory   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 [(4 FLUOROBENZYLOXY) 2,3 DIMETHYL 1 2 METHYLCYCLOPROPYLMETHYL] 1H PYRROLO[2,3 D]PYRIDAZINE; CS 526; GASTRIN; LANSOPRAZOLE; PROTON PUMP INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; DIALYSIS MEMBRANE; DRUG EFFECT; DRUG POTENCY; GASTRIN BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REBOUND; STOMACH ACID SECRETION; STOMACH ANTRUM; STOMACH BLOOD FLOW; STOMACH CONTENT; STOMACH ULCER; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; CIRCADIAN RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GASTRIC ACID; GASTRINS; MALE; PROTON PUMPS; PYRIDAZINES; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 45749140431     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.137299     Document Type: Article

References (30)

1. + ATPase inhibitor, 1-(2-methyl-4- methoxyphenyl)-4-[(3-hydroxypropyl) amino]-6-methyl-2,3-dihydropyrrolo[3,2- c]quinoline. Eur J Pharmacol 411:181-186.
2. Freston JW, Borch K, Brand SJ, Carlsson E, Creutzfeldt W, Hakanson R, Olbe L, Solcia E, Walsh JH, and Wolfe MM (1995) Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. A review and analysis. Dig Dis Sci 40 (2 Suppl):50S-62S.
3. 2 receptor antagonist. Gut 30:449-454.
4. +-ATPase. Biochem Pharmacol 73:198-205.
5. Gillen D and McColl KEL (2001) Problems related to acid rebound and tachphylaxis. Best Pract Res Clin Gastroenterol 15:487-495.
6. Gillen D, Wirz AA, Ardill JE, and McColl KEL (1999a) Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 116:239-247.
7. Gillen D, Wirz AA, Neithercut WD, Ardill JES, and McColl KEL (1999b) Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 44:468-475.
8. +-ATPase inhibitors. Prog Med Chem 31:233-264.
9. Ito K, Kinoshita K, Tomizawa A, Morikawa-Inomata Y, Inaba F, Makino M, Tabata K, and Shibakawa N (2007) Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2- methylcyclopropyl]methyl}-1Hpyrrolo[2,3-d]pyridazine (CS-526). J Pharmacol Exp Ther 323:308-317.
10. +)-ATPase. Biochem Pharmacol 42:123-130.
11. Kromer W, Postius S, and Riedel R (2000) Animal pharmacology of reversible antagonism of the gastric acid pump, compared to standard antisecretory principles. Pharmacology 60:179-187.
12. Kummer AF, Johnston DA, Marks IN, Young GO, Tigler-Wybrandi NA, and Bridger SA (1992) Changes in nocturnal and peak acid outputs after duodenal ulcer healing with sucralfate or ranitidine. Gut 33:175-178.
13. Laheij RJF, Sturkenboom MCJM, Hassing R-J, Dieleman J, Stricker BHC, and Jansen, JBMJ (2004) Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292:1955-1960.
14. Lamberts R, Creutzfeldt W, Stockmann F, Jacubaschke U, Maas S, and Brunner G (1988) Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 39:126-135.
15. Lamberts R, Creutzfeldt W, Struber HG, Brunner G, and Solcia E (1993) Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 104:1356-1370.
16. Larner AJ and Lendrum R (1992) Oesophageal candidiasis after omeprazole therapy. Gut 33:860-861.
17. Larsen KR, Moore JG, and Dayton MT (1991) Circadian rhythms of acid and bicarbonate efflux in fasting rat stomach. Am J Physiol Gastrointest Liver Physiol 260:G610-G614.
18. Larsson H, Carlsson E, Ryberg B, Fryklund J, and Wallmark B (1988) Rat parietal cell function after prolonged inhibition of gastric acid secretion. Am J Physiol Gastrointest Liver Physiol 254:G33-G39.
19. Lindberg P, Brandstrom A, Wallmark B, Mattsson H, Rikner L, and Hoffmann K-J (1990) Omeprazole: the first proton pump inhibitor. Med Res Rev 10:1-54.
20. 2 receptor blockade. Gut 32:1455-1460.
21. +)-ATPase, SK&F 97574. I. In vitro activity. Biochem Pharmacol 50:1543-1549.
22. +-transporting ATPase: a new class of anti-secretory agent. Trends Pharmacol Sci 14:323-325.
23. Postius S, Bräuer U, and Kromer W (1991) The novel proton pump inhibitor pantoprazole elevates intragastric pH for a prolonged period when administered under conditions of stimulated gastric acid secretion in the gastric fistula dog. Life Sci 49:1047-1052.
24. Robinson M (2001) New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol 13 (Suppl 1):S43-S47.
25. Robinson M (2005) Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int J Clin Pract 59:709-715.
26. Sachs G (1988) Gastric H,K-ATPase as therapeutic target. Annu Rev Pharmacol Toxicol 28:269-284.
27. Tari A, Hamada M, Kamiyasu T, Fukino Y, Sumii M, Sumii K, and Kajiyama G (1996) Effects of pirenzepine on omeprazole-induced gastrin gene expression in rat antral tissues. Dig Dis Sci 41:1150-1156.
28. Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, and Sandvik AK (1996) Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 39:649-653.
29. +-ATPase and acid secretion by SCH28080, a substituted pyridyl(1,2a)imidazole. J Biol Chem 262:2077-2084.
30. 2-receptor antagonists. Dig Dis Sci 35:976-983.